Combinatorial Intervention with Mesenchymal Stem Cells and Granulocyte Colony-Stimulating Factor in a Rat Model of Ulcerative Colitis

Digestive Diseases and Sciences

Volumn 60, Issue 7, 2015, Pages 1948-1957

  Tang, YinHua ^a   Chen, YingYing ^a   Wang, Xi ^a   Song, Guang ^a   Li, YongGuo ^a   Shi, LiJun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Granulocyte colony stimulating factor (G CSF); Mesenchymal stem cell (MSC); Transplantation; Ulcerative colitis (UC)

Indexed keywords

ANTIINFLAMMATORY AGENT; BROXURIDINE; CD34 ANTIGEN; CD45 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESALAZINE; MYELOPEROXIDASE; THY 1 ANTIGEN; TRANSCRIPTION FACTOR RELA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADHERENT CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SHAPE; CELL SIZE; COLON MUCOSA; COLON ULCER; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; IMMUNOFLUORESCENCE; IN VITRO STUDY; LAMINA PROPRIA; MACROPHAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINDLE CELL; STROMA CELL; ULCERATIVE COLITIS; ANIMAL; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; GENE EXPRESSION REGULATION; INFLAMMATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; COLITIS, ULCERATIVE; GENE EXPRESSION REGULATION; GRANULOCYTE COLONY-STIMULATING FACTOR; INFLAMMATION; MESALAMINE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RATS; SEVERITY OF ILLNESS INDEX; TRINITROBENZENESULFONIC ACID;

EID: 84930821734     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3655-3     Document Type: Article

References (39)

1. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14:3937–3947.
2. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010;42:332–337.
3. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13:R79.
4. Preda CM, Vermeire S, Rutgeerts P, et al. Prevalence and significance of perinuclear anti-neutrophil antibodies (pANCA) in Romanian patients with Crohn’s disease and ulcerative colitis. Rom J Gastroenterol. 2005;14:357–360.
5. Ebert EC, Geng X, Lin J, et al. Autoantibodies against human tropomyosin isoform 5 in ulcerative colitis destroys colonic epithelial cells through antibody and complement-mediated lysis. Cell Immunol. 2006;244:43–49.
6. Ebert EC, Geng X, Bajpai M, et al. Antibody to tropomyosin isoform 5 and complement induce the lysis of colonocytes in ulcerative colitis. Am J Gastroenterol. 2009;104:2996–3003.
7. Veltkamp C, Anstaett M, Wahl K, et al. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFalpha treatment. Gut. 2011;60:1345–1353.
8. Fuss IJ, Strober W. The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol. 2008;1:S31–S33.
9. Nishihira J, Mitsuyama K. Overview of the role of macrophage migration inhibitory factor (MIF) in inflammatory bowel disease. Curr Pharm Des. 2009;15:2104–2109.
10. Martinesi M, Treves C, Bonanomi AG, et al. Down-regulation of adhesion molecules and matrix metalloproteinases by ZK 156979 in inflammatory bowel diseases. Clin Immunol. 2010;136:51–60.
11. Sanchez-Munoz F, Fonseca-Camarillo G, Villeda-Ramirez MA, et al. Transcript levels of Toll-Like receptors 5, 8 and 9 correlate with inflammatory activity in ulcerative colitis. BMC Gastroenterol. 2011;11:138.
12. Wu Y, Wang J, Scott PG, et al. Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen. 2007;15:S18–S26.
13. Kuo TK, Hung SP, Chuang CH, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134:2111–2121.
14. Hayashi Y, Tsuji S, Tsujii M, et al. Topical implantation of mesenchymal stem cells has beneficial effects on healing of experimental colitis in rats. J Pharmacol Exp Ther. 2008;326:523–531.
15. He XW, He XS, Lian L, et al. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig Dis Sci. 2012;57:3136–3144.
16. Lazebnik LB, Knyazev OV, Parfenov AI, et al. Optimization of cell therapy in patients with inflammatory bowel diseases. Ter Arkh. 2012;84:10–17.
17. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer. 2010;10:425–434.
18. Harbord MW, Marks DJ, Forbes A, et al. Impaired neutrophil chemotaxis in Crohn’s disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment Pharmacol Ther. 2006;24:651–660.
19. Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J Exp Med. 2009;206:1883–1897.
20. Casanova JL, Abel L. Revisiting Crohn’s disease as a primary immunodeficiency of macrophages. J Exp Med. 2009;206:1839–1843.
21. Motavallian A, Minaiyan M, Rabbani M, et al. Does cisapride, as a 5HT4 receptor agonist, aggravate the severity of TNBS-induced colitis in rat? Gastroenterol Res Pract. 2012;2012:362536.
22. Zhang M, Long Y, Sun Y, et al. Evidence for the complementary and synergistic effects of the three-alkaloid combination regimen containing berberine, hypaconitine and skimmianine on the ulcerative colitis rats induced by trinitrobenzene-sulfonic acid. Eur J Pharmacol. 2011;651:187–196.
23. Guo X, Liu ES, Ko JK, et al. Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. Eur J Pharmacol. 2001;411:193–203.
24. Deng X, Tolstanova G, Khomenko T, et al. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine. J Phamracol Exp Ther. 2009;331:1071–1078.
25. Vowinkel T, Kalogeris TJ, Mori M, et al. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 2004;49:556–564.
26. Fedorak RN, Empey LR, MacArthur C, et al. Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology. 1990;98:615–625.
27. Kashyap A, Forman SJ. Autologous bone marrow transplantation for non-Hodgkin’s lymphoma resulting in long-term remission of coincidental Crohn’s disease. Br J Haematol. 1998;103:651–652.
28. Brittan M, Alison MR, Schier S, et al. Bone marrow stem cell-mediated regeneration in IBD: where do we go from here? Gastroenterology. 2007;132:1171–1173.
29. Ricart E. Current status of mesenchymal stem cell therapy and bone marrow transplantation in IBD. Dig Dis (Basel, Switz). 2012;30:387–391.
30. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 1997;27:1743–1750.
31. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996;2:998–1004.
32. Shouval DS, Ouahed J, Biswas A, et al. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol. 2014;122:177–210.
33. − mice. Immunobiology. 2013;218:1439–1451.
34. Chadwick VS, Schlup MM, Ferry DM, et al. Measurements of unsaturated vitamin B12-binding capacity and myeloperoxidase as indices of severity of acute inflammation in serial colonoscopy biopsy specimens from patients with inflammatory bowel disease. Scand J Gastroenterol. 1990;25:1196–1204.
35. Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J. 1998;45:69–73.
36. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001;107:7–11.
37. Chang YJ, Huang XJ. Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation. Beijing Da Xue Xue Bao. 2009;41:208–211.
38. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–3843.
39. Egi H, Hayamizu K, Yoshimitsu M, et al. Regulation of T helper type-1 immunity in hapten-induced colitis by host pretreatment with granulocyte colony-stimulating factor. Cytokine. 2003;23:23–30.